We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis

MedXY Editorial Team•Dec 10, 2025•news
chemotherapyChildhood Cancer Survivorscolorectal cancer

Highlights

– In 25,723 five‑year childhood cancer survivors (median follow‑up 28.5 years), colorectal subsequent malignant neoplasms (SMNs) were strongly associated with mean colorectum dose (MCD) and irradiated colorectal volume in a dose‑dependent manner.

– Specific chemotherapy exposures showed independent and dose‑dependent risks: procarbazine demonstrated a steep linear excess rate ratio (ERR) per 1,000 mg/m2, and high cumulative doses of alkylators and platinum were also associated with markedly increased colorectal SMN incidence.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Neurotensin Receptor 1: A Key Driver of Immune Exclusion and Poor Prognosis in Colorectal CancerHigh expression of neurotensin receptor 1 (NTSR1) defines an immune-cold colorectal cancer subtype linked to worse outcomes by creating mechanical and biological barriers that exclude T-cell infiltration, highlighting a novel immunotherapeuSep 23, 2026Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter RegistryA multicenter German registry study comparing carboplatin/paclitaxel to other chemotherapy regimens in anaplastic thyroid cancer found no survival advantage, highlighting the importance of molecular diagnostics and multimodal treatment apprSep 21, 2026Age, Anthracycline Use, and Mortality Outcomes in Classic Hodgkin Lymphoma: Insights from a Large Complete Population CohortThis review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.Sep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive the
Sep 21, 2026
Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort StudyThis international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in aSep 17, 2026
New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to KnowAn international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC bSep 15, 2026